A multicenter, randomized, double-blind, placebo controlled, parallel group, adaptive design, efficacy and tolerability study of 4 fixed doses of DVS-233 [desvenlafaxine] in adult outpatients with fibromyalgia syndrome

Trial Profile

A multicenter, randomized, double-blind, placebo controlled, parallel group, adaptive design, efficacy and tolerability study of 4 fixed doses of DVS-233 [desvenlafaxine] in adult outpatients with fibromyalgia syndrome

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 12 Feb 2007 Status change
    • 02 Feb 2007 New trial centres added.
    • 08 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top